CN102488921B - 与钾或镁离子具有螯合作用的物质在提高磷酸镁水泥生物相容性助剂中的应用及磷酸镁水泥 - Google Patents
与钾或镁离子具有螯合作用的物质在提高磷酸镁水泥生物相容性助剂中的应用及磷酸镁水泥 Download PDFInfo
- Publication number
- CN102488921B CN102488921B CN 201110434323 CN201110434323A CN102488921B CN 102488921 B CN102488921 B CN 102488921B CN 201110434323 CN201110434323 CN 201110434323 CN 201110434323 A CN201110434323 A CN 201110434323A CN 102488921 B CN102488921 B CN 102488921B
- Authority
- CN
- China
- Prior art keywords
- magnesium
- phosphate
- phosphate cement
- potassium
- magnesium phosphate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000004568 cement Substances 0.000 title claims abstract description 51
- 229910000157 magnesium phosphate Inorganic materials 0.000 title claims abstract description 47
- 239000004137 magnesium phosphate Substances 0.000 title claims abstract description 47
- 229960002261 magnesium phosphate Drugs 0.000 title claims abstract description 47
- 235000010994 magnesium phosphates Nutrition 0.000 title claims abstract description 47
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 title claims abstract description 45
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 title claims abstract description 16
- 229910001425 magnesium ion Inorganic materials 0.000 title claims abstract description 16
- 229910001414 potassium ion Inorganic materials 0.000 title claims abstract description 15
- 239000012752 auxiliary agent Substances 0.000 title claims abstract description 12
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 title claims abstract description 9
- 239000011591 potassium Substances 0.000 title claims abstract description 9
- 230000002708 enhancing effect Effects 0.000 title abstract 4
- 239000000126 substance Substances 0.000 title abstract 2
- 150000001413 amino acids Chemical class 0.000 claims abstract description 31
- 239000000203 mixture Substances 0.000 claims abstract description 27
- 230000009920 chelation Effects 0.000 claims abstract description 11
- 239000000463 material Substances 0.000 claims description 71
- 239000000843 powder Substances 0.000 claims description 39
- 235000001014 amino acid Nutrition 0.000 claims description 29
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 29
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 22
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 22
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical group [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 22
- 239000000395 magnesium oxide Substances 0.000 claims description 20
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 20
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 20
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 19
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 19
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 19
- QQFLQYOOQVLGTQ-UHFFFAOYSA-L magnesium;dihydrogen phosphate Chemical compound [Mg+2].OP(O)([O-])=O.OP(O)([O-])=O QQFLQYOOQVLGTQ-UHFFFAOYSA-L 0.000 claims description 17
- 229910000401 monomagnesium phosphate Inorganic materials 0.000 claims description 17
- 235000019785 monomagnesium phosphate Nutrition 0.000 claims description 17
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 16
- MSXHSNHNTORCAW-GGLLEASOSA-M sodium;(2s,3s,4s,5r,6s)-3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].O[C@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O MSXHSNHNTORCAW-GGLLEASOSA-M 0.000 claims description 15
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 13
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 13
- MLSJBGYKDYSOAE-DCWMUDTNSA-N L-Ascorbic acid-2-glucoside Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1O MLSJBGYKDYSOAE-DCWMUDTNSA-N 0.000 claims description 13
- 229930195725 Mannitol Natural products 0.000 claims description 13
- 239000000594 mannitol Substances 0.000 claims description 13
- 235000010355 mannitol Nutrition 0.000 claims description 13
- 239000000600 sorbitol Substances 0.000 claims description 13
- 235000010356 sorbitol Nutrition 0.000 claims description 13
- 235000011132 calcium sulphate Nutrition 0.000 claims description 12
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 11
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 11
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 11
- 235000003704 aspartic acid Nutrition 0.000 claims description 11
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 11
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 11
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 11
- 239000000811 xylitol Substances 0.000 claims description 11
- 235000010447 xylitol Nutrition 0.000 claims description 11
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 11
- 229960002675 xylitol Drugs 0.000 claims description 11
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 10
- 235000013922 glutamic acid Nutrition 0.000 claims description 10
- 239000004220 glutamic acid Substances 0.000 claims description 10
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 claims description 9
- 239000004471 Glycine Substances 0.000 claims description 8
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 8
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 8
- 229910019142 PO4 Inorganic materials 0.000 claims description 8
- 229930182817 methionine Natural products 0.000 claims description 8
- 239000010452 phosphate Substances 0.000 claims description 8
- 230000037396 body weight Effects 0.000 claims description 4
- 239000001175 calcium sulphate Substances 0.000 claims description 4
- 239000012620 biological material Substances 0.000 abstract description 21
- 230000015556 catabolic process Effects 0.000 abstract description 21
- 238000006731 degradation reaction Methods 0.000 abstract description 20
- 150000002500 ions Chemical class 0.000 abstract description 10
- 210000001124 body fluid Anatomy 0.000 abstract description 8
- 239000010839 body fluid Substances 0.000 abstract description 8
- 229910021645 metal ion Inorganic materials 0.000 abstract description 7
- 231100000419 toxicity Toxicity 0.000 abstract description 6
- 230000001988 toxicity Effects 0.000 abstract description 6
- 239000013522 chelant Substances 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 4
- 239000002738 chelating agent Substances 0.000 abstract description 3
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 235000021092 sugar substitutes Nutrition 0.000 abstract 1
- 239000003765 sweetening agent Substances 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 25
- 210000000988 bone and bone Anatomy 0.000 description 22
- 230000000052 comparative effect Effects 0.000 description 14
- 238000012360 testing method Methods 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 10
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 9
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 9
- 239000000654 additive Substances 0.000 description 8
- 230000037237 body shape Effects 0.000 description 8
- 230000004663 cell proliferation Effects 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 206010011732 Cyst Diseases 0.000 description 7
- 229930006000 Sucrose Natural products 0.000 description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 7
- 150000001720 carbohydrates Chemical class 0.000 description 7
- 208000031513 cyst Diseases 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- -1 phosphate anion Chemical class 0.000 description 7
- 239000005720 sucrose Substances 0.000 description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 6
- 230000000996 additive effect Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 238000005297 material degradation process Methods 0.000 description 6
- 230000002378 acidificating effect Effects 0.000 description 5
- 150000003863 ammonium salts Chemical class 0.000 description 5
- YYRMJZQKEFZXMX-UHFFFAOYSA-N calcium;phosphoric acid Chemical compound [Ca+2].OP(O)(O)=O.OP(O)(O)=O YYRMJZQKEFZXMX-UHFFFAOYSA-N 0.000 description 5
- 239000002426 superphosphate Substances 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 239000007943 implant Substances 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000002639 bone cement Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000000919 ceramic Substances 0.000 description 3
- 208000037976 chronic inflammation Diseases 0.000 description 3
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002787 reinforcement Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 2
- 208000001889 Acid-Base Imbalance Diseases 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 206010014418 Electrolyte imbalance Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- LFVGISIMTYGQHF-UHFFFAOYSA-N ammonium dihydrogen phosphate Chemical compound [NH4+].OP(O)([O-])=O LFVGISIMTYGQHF-UHFFFAOYSA-N 0.000 description 2
- 229910052925 anhydrite Inorganic materials 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000010478 bone regeneration Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000007596 consolidation process Methods 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- 210000003041 ligament Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 229910044991 metal oxide Inorganic materials 0.000 description 2
- 150000004706 metal oxides Chemical class 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 229910001415 sodium ion Inorganic materials 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 229910014497 Ca10(PO4)6(OH)2 Inorganic materials 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 241000446313 Lamella Species 0.000 description 1
- 206010062049 Lymphocytic infiltration Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- ZQBZAOZWBKABNC-UHFFFAOYSA-N [P].[Ca] Chemical compound [P].[Ca] ZQBZAOZWBKABNC-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000003364 biologic glue Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 229910010293 ceramic material Inorganic materials 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000004035 construction material Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000222 eosinocyte Anatomy 0.000 description 1
- 210000002745 epiphysis Anatomy 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 238000010231 histologic analysis Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000008040 ionic compounds Chemical class 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 238000009940 knitting Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000021962 pH elevation Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 238000007712 rapid solidification Methods 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 239000012779 reinforcing material Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Landscapes
- Materials For Medical Uses (AREA)
Abstract
Description
样品 | 所含糖类化合物 | 细胞增殖率 |
1 | 葡萄糖酸钠 | 93.2% |
2 | 维生素C糖苷 | 91.8% |
3 | 甘露醇 | 91.4% |
4 | 山梨醇 | 92.3% |
5 | 木糖醇 | 89.7% |
6 | 维生素C糖苷和甘露醇 | 94.2% |
7 | 葡萄糖酸钠和山梨醇 | 96.5% |
8 | 蔗糖 | 88.6% |
对比实施例 | 蔗糖 | 81.3% |
样品 | 所含氨基酸 | 细胞增殖率 |
1 | 谷氨酸 | 86.2% |
2 | 天冬氨酸 | 86.8% |
3 | 甘氨酸 | 85.9% |
4 | 蛋氨酸 | 85.3% |
5 | 谷氨酸和蛋氨酸 | 87.7% |
6 | 天冬氨酸和甘氨酸 | 88.6% |
7 | 无 | 84.4% |
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110434323 CN102488921B (zh) | 2011-12-22 | 2011-12-22 | 与钾或镁离子具有螯合作用的物质在提高磷酸镁水泥生物相容性助剂中的应用及磷酸镁水泥 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110434323 CN102488921B (zh) | 2011-12-22 | 2011-12-22 | 与钾或镁离子具有螯合作用的物质在提高磷酸镁水泥生物相容性助剂中的应用及磷酸镁水泥 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102488921A CN102488921A (zh) | 2012-06-13 |
CN102488921B true CN102488921B (zh) | 2013-10-16 |
Family
ID=46180813
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201110434323 Expired - Fee Related CN102488921B (zh) | 2011-12-22 | 2011-12-22 | 与钾或镁离子具有螯合作用的物质在提高磷酸镁水泥生物相容性助剂中的应用及磷酸镁水泥 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102488921B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103407980B (zh) * | 2013-07-16 | 2015-06-24 | 西安理工大学 | 磷酸镁医用骨粘结剂的制备方法 |
CN115818993A (zh) * | 2022-11-07 | 2023-03-21 | 江苏科技大学 | 一种耐水型磷酸镁水泥及其制备方法 |
CN116354632B (zh) * | 2023-06-01 | 2023-08-15 | 天津市镁诺生物技术有限公司 | 一种提供促进骨再生微环境的磷酸镁骨水泥及其制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009105614A2 (en) * | 2008-02-22 | 2009-08-27 | Dermal Technologies, Llc | Compositions for tissue augmentation |
CN101555177A (zh) * | 2009-01-20 | 2009-10-14 | 袁磊 | 一种有机酸钾营养剂 |
CN102240255A (zh) * | 2011-05-19 | 2011-11-16 | 李明贞 | 含酪氨酸酶抑制剂的美白组合物 |
CN102274543A (zh) * | 2011-08-01 | 2011-12-14 | 天津美基生物医药科技有限公司 | 镁基骨填充粘合剂及其制备方法与应用 |
CN102515576A (zh) * | 2011-12-05 | 2012-06-27 | 苏州达普生物技术有限公司 | 磷酸镁水泥用氧化镁及其制备方法和磷酸镁水泥 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10032220A1 (de) * | 2000-07-03 | 2002-01-24 | Sanatis Gmbh | Magnesium-ammonium-phosphat-Zemente, deren Herstellung und Verwendung |
-
2011
- 2011-12-22 CN CN 201110434323 patent/CN102488921B/zh not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009105614A2 (en) * | 2008-02-22 | 2009-08-27 | Dermal Technologies, Llc | Compositions for tissue augmentation |
CN101555177A (zh) * | 2009-01-20 | 2009-10-14 | 袁磊 | 一种有机酸钾营养剂 |
CN102240255A (zh) * | 2011-05-19 | 2011-11-16 | 李明贞 | 含酪氨酸酶抑制剂的美白组合物 |
CN102274543A (zh) * | 2011-08-01 | 2011-12-14 | 天津美基生物医药科技有限公司 | 镁基骨填充粘合剂及其制备方法与应用 |
CN102515576A (zh) * | 2011-12-05 | 2012-06-27 | 苏州达普生物技术有限公司 | 磷酸镁水泥用氧化镁及其制备方法和磷酸镁水泥 |
Non-Patent Citations (3)
Title |
---|
刘子胜等.无机骨粘合剂-磷酸镁骨水泥的研究进展.《材料导报》.2000,29-32. |
周公度主编.化学辞典.《化学辞典》.2004,第534、232、608、499、254、679、231、337页. * |
无机骨粘合剂-磷酸镁骨水泥的研究进展;刘子胜等;《材料导报》;20000531;29-32 * |
Also Published As
Publication number | Publication date |
---|---|
CN102488921A (zh) | 2012-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102515576B (zh) | 磷酸镁水泥用氧化镁及其制备方法和磷酸镁水泥 | |
EP1296909B1 (de) | Magnesium-ammonium-phosphat-zemente, deren herstellung und verwendung | |
EP1715829B1 (en) | Rapid-hardening calcium phosphate cement compositions | |
Hu et al. | Study on injectable and degradable cement of calcium sulphate and calcium phosphate for bone repair | |
CN102580144B (zh) | 外科用骨水泥及其制造方法 | |
Ambrosio et al. | Injectable calcium-phosphate-based composites for skeletal bone treatments | |
KR101276632B1 (ko) | 뼈 대체물로서 사용하기에 적합한 주입가능한 복합 물질 | |
AU2013358613B2 (en) | Cement-forming compositions, monetite cements, implants and methods for correcting bone defects | |
CN100496625C (zh) | 半水硫酸钙基复合的自固化生物活性材料、制备及应用 | |
TW201233398A (en) | Mineralized collagen-bioceramic composite and manufacturing method thereof | |
CN105251058B (zh) | 一种载药促骨生长注射型硫酸钙骨水泥的制备方法 | |
WO2014153127A1 (en) | Calcium phosphate cement compositions that set into high strength porous structures | |
CN103690994A (zh) | 一种海藻酸盐/羟基磷灰石水凝胶材料及其制备方法 | |
CN102488921B (zh) | 与钾或镁离子具有螯合作用的物质在提高磷酸镁水泥生物相容性助剂中的应用及磷酸镁水泥 | |
CN104591679A (zh) | 一种改性氯氧镁骨水泥及其制备方法和应用 | |
EP3111967A1 (en) | High strength synthetic bone for bone replacement for increasing compressive strength and facilitating blood circulation, and manufacturing method therefor | |
RU2494721C1 (ru) | Биосовместимый костнозамещающий материал и способ получения его | |
CN103830774A (zh) | 一种新型骨水泥及其制备方法 | |
JP2001314497A (ja) | 生体材料用組成物及びその硬化体 | |
El-Maghraby et al. | Preparation, structural characterization, and biomedical applications of gypsum-based nanocomposite bone cements | |
US20180264167A1 (en) | Cement-forming compositions, apatite cements, implants and methods for correcting bone defects | |
RU2552943C1 (ru) | Биодеградируемый материал для замещения костной ткани | |
RU2292868C1 (ru) | Материал для заполнения костных челюстно-лицевых и стоматологических дефектов | |
CN109091703B (zh) | 一种掺杂稀土元素的白磷矿/明胶三维多孔复合材料、其制备方法和应用 | |
CN104740680A (zh) | 一种镁基生物材料组合物及其制备方法与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: CHENGDU DAPU MEDICAL DEVICES CO., LTD. Effective date: 20130513 Owner name: HAN DAQING Free format text: FORMER OWNER: SUZHOU DAPU BIOLOGICAL TECHNOLOGY TECHNOLOGY CO., LTD. Effective date: 20130513 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: SUZHOU, JIANGSU PROVINCE TO: 110002 SHENYANG, LIAONING PROVINCE |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20130513 Address after: 110002, 2-6-2, 13 East embroidered Street East, Tiexi District, Liaoning, Shenyang Applicant after: Han Daqing Address before: Suzhou Industrial Park Xinghu Street No. 218 Building 1 layer A5 Applicant before: SUZHOU DAPU BIOTECHNOLOGY CO.,LTD. Applicant before: CHENGDU DAPU MEDICAL DEVICES Co.,Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20161031 Address after: 300380, building 10, building 35, 901, Xiqing Industrial Zone, Tianjin, China Patentee after: Tianjin magnesium Biological Technology Co.,Ltd. Address before: 13 2-6-2, 110002 East embroidery street, Tiexi District, Liaoning, Shenyang Patentee before: Han Daqing |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20131016 Termination date: 20211222 |